SEK 18.8
(2.73%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | -15 Thousand SEK | 0.0% |
2022 | -15 Thousand SEK | 0.0% |
2021 | -15 Thousand SEK | 90.68% |
2020 | -161 Thousand SEK | 44.48% |
2019 | -290 Thousand SEK | 98.71% |
2018 | -22.51 Million SEK | -842.22% |
2017 | -2.39 Million SEK | -20.16% |
2016 | -1.98 Million SEK | -136.5% |
2015 | -841 Thousand SEK | -107.62% |
2014 | 11.03 Million SEK | 34.29% |
2013 | 8.21 Million SEK | 14.11% |
2012 | 7.2 Million SEK | 151.27% |
2011 | 2.86 Million SEK | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q1 | - SEK | 0.0% |
2024 Q2 | - SEK | 0.0% |
2023 Q4 | - SEK | 0.0% |
2023 Q2 | - SEK | 0.0% |
2023 FY | -15 Thousand SEK | 0.0% |
2023 Q3 | - SEK | 0.0% |
2023 Q1 | - SEK | 0.0% |
2022 Q4 | - SEK | 0.0% |
2022 Q3 | - SEK | 0.0% |
2022 Q2 | - SEK | 0.0% |
2022 Q1 | - SEK | 0.0% |
2022 FY | -15 Thousand SEK | 0.0% |
2021 Q3 | - SEK | 0.0% |
2021 FY | -15 Thousand SEK | 90.68% |
2021 Q1 | -4000.00 SEK | 0.0% |
2021 Q2 | - SEK | 100.0% |
2021 Q4 | - SEK | 0.0% |
2020 Q1 | - SEK | 0.0% |
2020 Q3 | - SEK | 0.0% |
2020 Q4 | - SEK | 0.0% |
2020 FY | -161 Thousand SEK | 44.48% |
2020 Q2 | - SEK | 0.0% |
2019 FY | -290 Thousand SEK | 98.71% |
2019 Q3 | - SEK | 0.0% |
2019 Q4 | - SEK | 0.0% |
2019 Q1 | - SEK | 0.0% |
2019 Q2 | - SEK | 0.0% |
2018 Q1 | - SEK | 0.0% |
2018 Q4 | - SEK | 0.0% |
2018 Q3 | - SEK | 0.0% |
2018 FY | -22.51 Million SEK | -842.22% |
2018 Q2 | - SEK | 0.0% |
2017 Q3 | - SEK | 0.0% |
2017 Q1 | - SEK | 0.0% |
2017 Q4 | - SEK | 0.0% |
2017 FY | -2.39 Million SEK | -20.16% |
2017 Q2 | - SEK | 0.0% |
2016 FY | -1.98 Million SEK | -136.5% |
2016 Q3 | - SEK | 0.0% |
2016 Q4 | - SEK | 0.0% |
2016 Q2 | - SEK | 0.0% |
2016 Q1 | - SEK | 0.0% |
2015 Q2 | - SEK | -100.0% |
2015 Q3 | - SEK | 0.0% |
2015 Q1 | 2.7 Million SEK | 7.9% |
2015 Q4 | - SEK | 0.0% |
2015 FY | -841 Thousand SEK | -107.62% |
2014 FY | 11.03 Million SEK | 34.29% |
2014 Q4 | 2.5 Million SEK | -23.63% |
2014 Q3 | 3.28 Million SEK | 37.24% |
2014 Q2 | 2.39 Million SEK | -16.17% |
2014 Q1 | 2.85 Million SEK | 33.6% |
2013 Q4 | 2.13 Million SEK | -55.71% |
2013 FY | 8.21 Million SEK | 14.11% |
2013 Q2 | 4.28 Million SEK | 179.4% |
2013 Q1 | 1.53 Million SEK | -12.84% |
2013 Q3 | 4.81 Million SEK | 12.41% |
2012 Q4 | 1.76 Million SEK | -12.13% |
2012 Q3 | 2 Million SEK | 31.52% |
2012 FY | 7.2 Million SEK | 151.27% |
2012 Q2 | 1.52 Million SEK | 0.0% |
2011 FY | 2.86 Million SEK | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Alligator Bioscience AB (publ) | -160.68 Million SEK | 99.991% |
Ziccum AB (publ) | -23.28 Million SEK | 99.936% |
Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
BioArctic AB (publ) | 346.31 Million SEK | 100.004% |
Sprint Bioscience AB (publ) | 41.78 Million SEK | 100.036% |
Mendus AB (publ) | 28.48 Million SEK | 100.053% |
Genovis AB (publ.) | 54 Million SEK | 100.028% |
Intervacc AB (publ) | -13.79 Million SEK | 99.891% |
QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 100.691% |
Active Biotech AB (publ) | -1.67 Million SEK | 99.104% |
Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 100.151% |
Bio-Works Technologies AB (publ) | 26.82 Million SEK | 100.056% |
Aptahem AB (publ) | 2.63 Million SEK | 100.57% |
Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 99.562% |
Kancera AB (publ) | -1.96 Million SEK | 99.237% |
Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 119.481% |
Fluicell AB (publ) | 1.73 Million SEK | 100.863% |
Saniona AB (publ) | 11.78 Million SEK | 100.127% |
Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 99.707% |
Biovica International AB (publ) | 6.87 Million SEK | 100.218% |
Spago Nanomedical AB (publ) | -23.28 Million SEK | 99.936% |
AcouSort AB (publ) | 8.38 Million SEK | 100.179% |
Xintela AB (publ) | 78 Thousand SEK | 119.231% |
Abliva AB (publ) | -35.66 Million SEK | 99.958% |
Egetis Therapeutics AB (publ) | -146.9 Million SEK | 99.99% |
Karolinska Development AB (publ) | 2.8 Million SEK | 100.534% |
OncoZenge AB (publ) | 3000.00 SEK | 600.0% |
Amniotics AB (publ) | -1.93 Million SEK | 99.223% |
2cureX AB (publ) | -37.48 Million SEK | 99.96% |
CombiGene AB (publ) | -21.29 Million SEK | 99.93% |
Asarina Pharma AB (publ) | -423 Thousand SEK | 96.454% |
Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 100.001% |
Camurus AB (publ) | 1.58 Billion SEK | 100.001% |
Corline Biomedical AB | 28.38 Million SEK | 100.053% |
IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 99.988% |
Isofol Medical AB (publ) | -34.41 Million SEK | 99.956% |
I-Tech AB | 27.56 Million SEK | 100.054% |
Hansa Biopharma AB (publ) | 70.95 Million SEK | 100.021% |
Cyxone AB (publ) | 2.61 Million SEK | 100.574% |
ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 100.441% |
Biosergen AB | -456 Thousand SEK | 96.711% |
Cantargia AB (publ) | -3.45 Million SEK | 99.565% |
NextCell Pharma AB | -43.74 Million SEK | 99.966% |
Xspray Pharma AB (publ) | -9.19 Million SEK | 99.837% |
Elicera Therapeutics AB (publ) | 11.21 Million SEK | 100.134% |
Nanologica AB (publ) | -76 Thousand SEK | 80.263% |
SynAct Pharma AB | -778 Thousand SEK | 98.072% |
Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 92.228% |
Stayble Therapeutics AB (publ) | - SEK | Infinity% |
LIDDS AB (publ) | -12.92 Million SEK | 99.884% |
Lipum AB (publ) | 53 Thousand SEK | 128.302% |
BioInvent International AB (publ) | 71.46 Million SEK | 100.021% |
Alzinova AB (publ) | 19.87 Million SEK | 100.075% |
Oncopeptides AB (publ) | 36.29 Million SEK | 100.041% |
Pila Pharma AB (publ) | 1.46 Million SEK | 101.025% |
Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 100.905% |
Simris Alg AB (publ) | 2 Million SEK | 100.747% |
Diamyd Medical AB (publ) | -3.58 Million SEK | 99.581% |
Xbrane Biopharma AB (publ) | 35.38 Million SEK | 100.042% |
Ascelia Pharma AB (publ) | -1.04 Million SEK | 98.57% |
Diagonal Bio AB (publ) | 3.13 Million SEK | 100.479% |